

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Arispe et al.

Docket No.: PF453P3

Application No.: 09/989,687

Confirmation No.: 9708

Filed: November 21, 2001

Art Unit: 1643

For: METH1 and METH2 Polynucleotides and
Polypeptides

Examiner: K. A. Canella

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references CQ-DC listed on the attached Form SB/08. Copies of non-U.S. patent references CR-DC are enclosed.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.


The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a Request for Continued

Examination. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge such fee to our Deposit Account No. 08-3425.

Dated: September 8, 2006

Respectfully submitted,

By 
Melissa J. Pytel

Registration No.: 41,512
HUMAN GENOME SCIENCES, INC.
Intellectual Property Dept.
14200 Shady Grove Road
Rockville, Maryland 20850
(301) 610-5764

KKH/MJP/EC/mr

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/989,687-Conf. #9708
				Filing Date	November 21, 2001
				First Named Inventor	Luisa Iruela Arispe
				Art Unit	1643
				Examiner Name	K. A. Canella
Sheet	1	of	1	Attorney Docket Number	PF453P3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	CQ	09/373,658	05-15-2003	Iruela-Arispe, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	CR	WO 98/56804	12-17-1998	Human Genome Sciences, Inc.		
	CS	AU 36226/00 (Based on WO 00/53774)	09-28-2000	Neurocrine Biosciences, Inc.		
	CT	AU 766,787	08-09-1999	Human Genome Sciences, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CU	BREM, S. "Angiogenesis and Cancer Control: From Concept to Therapeutic Trial", <i>Cancer Control</i> , 1999, 6(5): 436-458.	
	CV	BROOKS, P.C., et al., "Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3", 1996, <i>Cell</i> 85(5): 683-93.	
	CW	DAS, R.C., "Proteins and antibodies make advances as therapeutic products", <i>American Biotechnology Laboratory</i> , 2000, 38-40.	
	CX	KANG, I.C., et al., "A novel disintegrin salmosin inhibits tumor angiogenesis", <i>Cancer Res.</i> , 1999, 59(15): 3754-60.	
	CY	MARKLAND, F.S., et al., "A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model", <i>Haemostasis</i> , 2001, 31(3-6): 183-91.	
	CZ	PAVLOU, A.K., et al., "Recombinant protein therapeutics--success rates, market trends and values to 2010", <i>Nat Biotechnol</i> , 2004, 22(12): 1513-9.	
	DA	SENGER, D.R., et al., "Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins", <i>Proc Natl Acad Sci USA</i> , 1997, 13612-7.	
	DB	YEH, C.H., et al., "Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis", <i>Blood</i> , 1998, 92(9): 3268-76.	
	DC	YEH, C.H., et al., "Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells", <i>Mol Pharmacol</i> , 2001, 59(5): 1333-42.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--